Mycobacterium bovis BCG priming induces a strong potentiation of the antibody response induced by recombinant BCG expressing a foreign antigen
Authors:
- 1 October 1994
- journal article
- research article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 62 (10) , 4287-4295
Abstract
Several recent studies have demonstrated that strong cellular or humoral immune responses can be induced against foreign antigens expressed by recombinant Mycobacterium bovis BCG. It has therefore been suggested that BCG could represent one of the best candidate vectors for live recombinant vaccines. However, a large percentage of the human population has been immunized by BCG, and this priming could modify the immune response to future recombinant BCG vaccines. In the present study, we have therefore compared the immune responses induced in naive and BCG-primed mice by two recombinant BCG vaccines expressing either beta-galactosidase or human immunodeficiency virus type 1 Nef antigens. Our results demonstrated that BCG priming limits the growth of recombinant BCG in mouse spleen or lymph nodes. This reduction in BCG growth was associated with decreased proliferative responses against Nef or beta-galactosidase antigens. This suppression, however, never exceeded 50%. Interestingly, in contrast to these reduced T-cell responses, BCG-primed mice developed high levels of anti-beta-galactosidase antibodies after immunization with recombinant BCG expressing this antigen. This stimulation of antibody responses was not due to polyclonal stimulation or to a nonspecific adjuvant effect of BCG. The isotypic patterns of anti-beta-galactosidase antibody responses induced by the recombinant BCG were similar in naive and BCG-primed mice. These results indicate that priming with BCG will not be a limitation for the use of recombinant BCG vaccines in humans.Keywords
This publication has 18 references indexed in Scilit:
- Oral immunization with recombinant BCG induces cellular and humoral immune responses against the foreign antigenVaccine, 1993
- Protective immunity elicited by recombinant bacille Calmette-Guerin (BCG) expressing outer surface protein A (OspA) lipoprotein: a candidate Lyme disease vaccine.Journal of Experimental Medicine, 1993
- BCG-induced protection in guinea pigs vaccinated and challenged via the respiratory routeTubercle and Lung Disease, 1993
- Tuberculosis: The Return of an Old EnemyCritical Reviews in Microbiology, 1993
- Expression of Escherichia coliβ‐galactosidase in Mycobacterium bovis BCG using an expression system isolated from Mycobacterium paratuberculosis which induced humoral and cellular immune responsesMolecular Microbiology, 1992
- Mycobacterial heat‐shock proteins as carrier molecules. II: The use of the 70‐kDa mycobacterial heat‐shock protein as carrier for conjugated vaccinescan circumvent the need for adjuvants and Bacillus Calmette Guérin priming)European Journal of Immunology, 1992
- Expression of heterologous genes in Mycobacterium bovis BCG: induction of a cellular response against HIV-1 Nef proteinGene, 1991
- Mycobacterial heat‐shock proteins as carrier moleculesEuropean Journal of Immunology, 1991
- New use of BCG for recombinant vaccinesNature, 1991
- Humoral and cell-mediated immune responses to live recombinant BCG–HIV vaccinesNature, 1991